n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
NORTHVALE, N. J. / ACCESSWIRE / Dec. 5, 2023 /ADM Tronics (OTCQB: ADMT) announced that its customer, Origin Life Sciences, Inc. (“Origin”) is in the process of initiating an IRB-approved pilot clinical study to compare the onychomycosis remedy using its plasma-generated nitric oxide (“NO”) technology. ADMT provided engineering, throttling, and production facilities to Origin in connection with the progression of the IonoJet™, which enables targeted delivery of plasma-generated NO. A current produced from the ambient air at the point of therapy.
Onychomycosis, a fungal infection of the nail that affects approximately 14% of the adult population, is not just a cosmetic problem. If left untreated, it can cause pain, discomfort, and physical impairment, negatively impacting quality of life. Oral antifungal remedies are effective, however, significant adverse effects restrict their use. Topical antifungal remedies have fewer side effects, but are less effective than oral antifungal remedies. Therefore, an effective non-invasive remedy option can have significant benefits for the tens of millions of people who suffer from this condition. .
According to Grand View Research, “the duration of the global onychomycosis market is estimated at $3. 44 billion in 2022 and is expected to grow at a compound annual expansion rate of 4. 56% through 2030. The onychomycosis market is growing due to factors such as increasing incidence. of onychomycosis and chronic diseases, expanding the R&D related to the progression of new drugs, as well as the development of the geriatric and diabetic population. https://www. grandviewresearch. com/industry-analysis/onychomycosis-marketplaceplace-report
Origin’s Ionojet™, a patented, non-invasive healing device, delivers healing amounts of NO directly to the treatment site. It uses a patented, high-energy plasma formula to convert nitrogen and oxygen from the air into a plasma/NO stream. Exploit this generation in the progression of cures for a variety of healing purposes, adding as an anti-infective, anti-inflammatory, and tissue regenerative cure for chronic wounds and skin and soft tissue infections.
A randomized, controlled clinical trial on the protection and dosing of Origin’s Ionojet™ conducted in 83 patients with diabetic foot ulcers (“UPDs”) who had an insufficient reaction to popular care, with promising results. Origin intends to conduct a pivotal DFU study and, if successful, submit an application for premarket approval to the FDA.
Onychomycosis is one of the next indications that Origin is pursuing, starting with this pilot study on 40 subjects presenting with fungal infected toenails, to be treated for 8 weeks with a 6-month follow-up, post therapy.
Origin contracted ADMT’s medical device engineering services for development of the Ionojet™ and for the production of study units used in the studies. ADMT developed and manufactured the Ionojet™ in its FDA-Registered, ISO-13485 Certified medical device development and manufacturing facility.
Michael Preston, President and CEO of Origin, said, “ADM Tronics has been and continues to be an integral partner with us in advancing our plasma healing technology. ADMT has helped us tremendously with their engineering, intellectual assets, and regulatory expertise in their paintings. For our specialty plasma healing products, we have global programs in many medical specialties. We look forward to continuing to work heavily with ADMT as we commercialize our medical technology.
About the origin
Origin Life Sciences, Inc. , in Princeton, New Jersey, is a clinical-stage biogeneration company that has developed, in collaboration with ADMT, its proprietary technology to generate and deliver nitric oxide in the form of high-energy/NO-current plasma. . . Visit originww. com.
About ADMT
ADMT is dedicated to advancing electronic therapeutic medical technologies. With a history of innovation and a commitment to improving healthcare, ADMT specializes in developing cutting-edge medical devices and therapies. ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Water-Based Formulations. The Company’s headquarters, laboratories, and FDA-Registered medical device manufacturing operations are located in Northvale, NJ. ADMT’s multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies.
ADMT welcomes inquiries for its electronics and medical device contract services at www.admteng.com.
Investor Relations:
Howard Isaacs 562-987-4939 HISAACS@EARTHLINK. NETRichard Cavalli 303-956-1777 RICHARDACAVALLI@GMAIL. COM
Except for historical information contained herein, the matters set forth in this news release are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT’s filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
SOURCE: ADM Tronics Unlimited, Inc.
View source version on accesswire.com: https://www.accesswire.com/813399/novel-therapeutic-technology-developed-manufactured-by-adm-tronics-for-origin-life-sciences-to-begin-clinical-study-on-onychomycosis